Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed/refractory acute myeloid leukemia (AML) except for acute promyelocytic leukemia
Eastern Cooperative Oncology Group status of 0 or 1
Adequate baseline renal and hepatic function
For Pre-allo Part A (before stem cell transplant): Relapsed or refractory AML (greater than 5% blasts)
For Pre-allo Part A (before stem cell transplant): Availability of an HLA matched related or unrelated donor
For Pre-allo Part A (before stem cell transplant): Eligible for an allogeneic hematopoietic stem cell transplant
For Post-allo Part B: Transplant must have been performed with active AML (greater than 5% blasts) using a conventional conditioning regimen and have achieved CR or CRi post-alloSCT (with ANC greater than or equal to 1,000 and platelet greater than or equal to 50,000)
For Post-allo Part B: Treatment must begin at least 42 days, but no more than 100 days post-transplant.
You may not be if
Inadequate heart function
Inadequate lung function
Previous central nervous system leukemia
Any history of another metastatic malignancy
Anti-leukemia treatment within14 days of study drug (other than hydroxyurea or 6-mercaptopurine), immunosuppressive therapy (except for GVHD treatment/prophylaxis in Part B), or investigational agents
For Pre-allo Part A (before stem cell transplant): Partially matched donors (related or unrelated) and umbilical cord blood cells are excluded as the source of hematopoietic stem cells
For Pre-allo Part A (before stem cell transplant): Prior alloSCT
For Post-allo Part B: Active GVHD Grade 2 or higher
For Post-allo Part B:History of veno-occlusive disease requiring defibrotide
For Post-allo Part B: History of Grade 2 or higher hepatic GVHD
For Post-allo Part B: Concurrent use of corticosteroids equivalent of prednisone at a dose of greater than 0.5 mg/kg
Clareo Health | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
